Select Page

OTS LaunchPad

We’re looking for the next big ophthalmology startup! Apply to our LaunchPad Accelerator for the chance to present in front of KOLs, investors and industry!

OTS Success Story Feature: LensGen

LensGen presented at Octane’s Ophthalmology Technology Summit in 2018 and raised a total of $42M.  They presented as the OTS Sucess Story as part of the LaunchPad Presentation Panel in 2019.

Our 2020 LaunchPad Finalists

cloudbreak therepeutics, ophthalmology company

Cloudbreak Therapeutics

Cloudbreak Therapeutics was founded in September 2015 at Irvine, CA by three ex-Allergan executives. Our company focuses on ophthalmic drug research and development. Cloudbreak Therapeutics has multiple on-going clinical and nonclinical programs to treat various eye diseases. The leading program, CBT-001, has successfully completed Phase II clinical trial in USA to treat pterygium and is ready to proceed with global Phase III clinical trials after a successful EOP2 meeting with the FDA. CBT-001 would be the disease-modifying, first-in-class and first drug therapy to treat pterygium, a large unmet medical need, and the projected global market size is over US$1 billion.

Learn More. 

leo lens pharma logo, launchpad finalists

Leo Lens Pharma

Leo Lens Pharma (Leo Lens) is an emerging San Diego-based pharmaceutical company focused on helping protect sight. Using its proprietary MediPrint™ process, the Company will commercialize a drug-eluting, comfort-enhancing therapeutic contact lens to treat millions of patients worldwide. While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they have only around a 50% compliance rate. This leads millions to suffer from disease progression. Leo Lens is currently focused on advancing its lead asset, a unique glaucoma treatment, to the clinic while continuing to build out its product pipeline.

Learn More. 

optify logo, black text


We’re eyewear industry and software execs building e-commerce software (SaaS) to help optometrists thrive in the digital age. 

30k+ independent optometrists distributed over 16k practices in the USA alone continue to write Rx’s each year for the vast majority of 225M eyeglass wearers. That number is increasing annually. Through Rx’s they write, they have direct access to an annual $14Bn USA frame/lens market. 

We are leveraging the software and patented tech that we’ve built and successfully deployed. We are extending this platform to all optometrists to sell any optical frame/brand with Rx lenses online. E-commerce has lagged for various industry specific reasons–including in-network insurance, proper measurements, etc. Optify is a turnkey solution. Today, we have 45 optometrists onboard and we are generating revenue.

Learn More. 

phileas pharma inc logo

Phileas Pharma

Phileas is a transformative biotech company developing proprietary inhibitors of the isoforms of TGF-β to treat age-related diseases with an initial focus on ophthalmology and fibrotic diseases using antisense oligonucleotides. Building on 2 decades of cumulative experience, Phileas has the only team ready to hit the road running with a complete development blueprint.  Our upcoming Institute of Vision collaboration represents a scientific validation of our approach, while reducing capital needs. Phileas plans to exit before commercialization, a major business opportunity in the context of the expanding M&A RNA therapeutic market. The company is currently raising a $1.5M seed round.

Learn More.